1Tokunage M,Saito K,Kawabata D,et al.Efficacy of rituximab(anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Ann Rheum Dis,2007,66:470-475.
2Saito K,Nawata M,Nakayamada S,et al.Successful treatment with anti-CD20 monoclonal antibody(rituximab)of life-threatening refractory systemic lupus erythmatosus with renal and central nervous system involvement.Lupus,2003,12:798-800.
3Perrotta S,Locatelli F,La Manna A,et al.anti-CD20 monoclonal antibody(Rituximab)for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.Br J Haematol,2002,116:465-467.
4Gunnarsson I,Sundelin B,Jonsdottir T,et al.Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.Arthritis Rheum,2007,56(4):1263-1272.
5Sturfelt G,Roux-Lombard P,Wollheim FA,et al.Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus.Br J Rheumatol,1997,36:1283-1289.
7Moosig F,Zeuner R,Renk C,et al.IL-1RA in refractory systemic lupus erythematosus.Lupus,2004,13(8):605-606.
8Osdor F,Iking-Konert R,Sander O,et al.Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.Ann Rheum Dis,2005,64:630-633.
9Furie R,Stohl W,Ginzler E,et al.Safety,pharmacokinetics and pharmacodynamic results of a phaseⅠsingle and double dose escalation study of lymphostat B in SLE patients.Arthritis Rheum,2003,48:S377.
10Stohl W.Therapeutic targeting of B lymphocyte stimulator(BLyS)in the rheumatic diseases.Endocr Metab Immune Disord Drug Targets,2006,6(4):351-358.
